Author Of 1 Presentation
TC08.02 - Presentation 02 (ID 612)
Abstract
Abstract
The gut microbiome is now considered among the risk factors associated with autoimmune diseases including Multiple Sclerosis (MS). This presentation is an overview of how gut dysbiosis potentially contributes to multiple sclerosis immunopathogenesis based on findings from the animal model experimental autoimmune encephalomyelitis (EAE) as well as MS human data. The presentation will demonstrate how gut dysbiosis influences neuroinflammation in EAE in an age dependent fashion and in the context of other MS risk factors including MHC class-II and MBP-specific TCR. The associated immune mechanisms will be described. Human data on gut microbiota species and taxa will be reviewed. Disease modifying therapies for MS seem to alter gut microbiota and immune responses in the gut through a variety of mechanisms including immune cell trafficking, gut barrier stabilization, and induction of T- regulatory cells. Finally, potential therapeutic interventions targeting the gut in MS will be reviewed including probiotics, antibiotics, fecal transplantation, diet and immune tolerance.
Presenter Of 1 Presentation
TC08.02 - Presentation 02 (ID 612)
Abstract
Abstract
The gut microbiome is now considered among the risk factors associated with autoimmune diseases including Multiple Sclerosis (MS). This presentation is an overview of how gut dysbiosis potentially contributes to multiple sclerosis immunopathogenesis based on findings from the animal model experimental autoimmune encephalomyelitis (EAE) as well as MS human data. The presentation will demonstrate how gut dysbiosis influences neuroinflammation in EAE in an age dependent fashion and in the context of other MS risk factors including MHC class-II and MBP-specific TCR. The associated immune mechanisms will be described. Human data on gut microbiota species and taxa will be reviewed. Disease modifying therapies for MS seem to alter gut microbiota and immune responses in the gut through a variety of mechanisms including immune cell trafficking, gut barrier stabilization, and induction of T- regulatory cells. Finally, potential therapeutic interventions targeting the gut in MS will be reviewed including probiotics, antibiotics, fecal transplantation, diet and immune tolerance.
Moderator Of 1 Session
Invited Speaker Of 1 Presentation
TC08.02 - Presentation 02 (ID 612)
Abstract
Abstract
The gut microbiome is now considered among the risk factors associated with autoimmune diseases including Multiple Sclerosis (MS). This presentation is an overview of how gut dysbiosis potentially contributes to multiple sclerosis immunopathogenesis based on findings from the animal model experimental autoimmune encephalomyelitis (EAE) as well as MS human data. The presentation will demonstrate how gut dysbiosis influences neuroinflammation in EAE in an age dependent fashion and in the context of other MS risk factors including MHC class-II and MBP-specific TCR. The associated immune mechanisms will be described. Human data on gut microbiota species and taxa will be reviewed. Disease modifying therapies for MS seem to alter gut microbiota and immune responses in the gut through a variety of mechanisms including immune cell trafficking, gut barrier stabilization, and induction of T- regulatory cells. Finally, potential therapeutic interventions targeting the gut in MS will be reviewed including probiotics, antibiotics, fecal transplantation, diet and immune tolerance.